DALLAS, December 7, 2011 /PRNewswire/ --
The report "Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in regions such as North America, & Europe.
Browse market data tables and in-depth TOC on Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020). http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukem... Early buyers will receive 10% customization on reports.
In acute lymphocytic leukemia, the body rapidly produces a large number of immature white blood cells, called lymphocytes. These immature white blood cells replace normal cells in the bone marrow. This type of cancer accounts for about 12% of the total leukemia. This type of cancer can be sub-categorized into childhood acute lymphocytic leukemia and adult acute lymphocytic leukemia.
Acute lymphocytic leukemia (ALL) is the most common type of leukemia in young children. This disease also affects adults, especially those aged 65 and older. Standard treatments involve chemotherapy and radiotherapy. The survival rates vary by age: 85% in children and 50% in adults. Subtypes include precursor B acute lymphocytic leukemia, precursor T acute lymphocytic leukemia, Burkitt leukemia, and acute biphenotypic leukemia.
The acute lymphocytic leukemia therapeutics market [ http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukem... ] was valued at $1.96 billion in 2010 and is expected to reach $3.88 billion by 2020, at a CAGR of 5.21% between 2015 and 2020. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen. The chemotherapy drug regimens were dominated by Hyper-CVAD regimen sales, totaling $1.8 billion and linker regimen sales totaling $1.13 billion sales in acute lymphocytic leukemia market.
According to WHO, acute lymphocytic leukemia is expected to be more prominent in the in more developed countries and higher socioeconomic groups such as North America and European countries due to genetic factor. Other causes like environmental factor and exposure to high doses of radiation are also the causative factors of all the types of acute lymphocytic leukemia.
The U.S. dominates the North American leukemia drug market with a 90% share; whereas Germany dominates the European market with 35% share.
Major players in the market include Ambit Biosciences Inc. (U.S.), ERYtech Pharma (France), Talon Therapeutic Inc. (U.S.), and Genzyme Corporation. (U.S.).